Literature DB >> 26832163

Kidney cancer: Sunitinib versus everolimus for non-clear-cell renal cell carcinoma.

Rebecca Kelsey.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26832163     DOI: 10.1038/nrurol.2016.25

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.

Authors:  Andrew J Armstrong; Susan Halabi; Tim Eisen; Samuel Broderick; Walter M Stadler; Robert J Jones; Jorge A Garcia; Ulka N Vaishampayan; Joel Picus; Robert E Hawkins; John D Hainsworth; Christian K Kollmannsberger; Theodore F Logan; Igor Puzanov; Lisa M Pickering; Christopher W Ryan; Andrew Protheroe; Christine M Lusk; Sadie Oberg; Daniel J George
Journal:  Lancet Oncol       Date:  2016-01-13       Impact factor: 41.316

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.